ERNA · Company research
Ernexa Therapeutics Inc. Common Stock (ERNA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| In animal tests, cell therapy plus immune treatment fully controlled ovarian tumors in most animals. - Stock Titan | In animal tests, cell therapy plus immune treatment fully controlled ovarian tumors in most animals. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| An ovarian cancer model showed 100% survival with a treatment combination. Human testing is planned for early 2027. - Stock Titan | An ovarian cancer model showed 100% survival with a treatment combination. Human testing is planned for early 2027. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial - StocksToTrade | ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial StocksToTrade | View source ↗ | StocksToTrade | Jul 15, 2026 | neutral | 0 | 0.6 |
| Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Yahoo Finance | Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| Ernexa Therapeutics stock surges 30% on preclinical data - Investing.com | Ernexa Therapeutics stock surges 30% on preclinical data Investing.com | View source ↗ | Investing.com | Jul 15, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Pops As Ernexa Flags Progress Toward First Trials - StocksToTrade | ERNA Stock Pops As Ernexa Flags Progress Toward First Trials StocksToTrade | View source ↗ | StocksToTrade | Jul 15, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - Yahoo Finance | ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | May 20, 2026 | neutral | 0 | 0.6 |
| $ERNA stock is down 18% today. Here's what we see in our data. - Quiver Quantitative | $ERNA stock is down 18% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | May 14, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts - Stocktwits | ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts Stocktwits | View source ↗ | Stocktwits | May 12, 2026 | neutral | 0 | 0.6 |
| Ernexa Stock Is Jumping Today: What's Going On? - Ernexa Therapeutics (NASDAQ:ERNA) - Benzinga | Ernexa Stock Is Jumping Today: What's Going On? - Ernexa Therapeutics (NASDAQ:ERNA) Benzinga | View source ↗ | Benzinga | May 12, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Skyrockets After ERNA-101 Delivers Tumor Clearance - Timothy Sykes | ERNA Stock Skyrockets After ERNA-101 Delivers Tumor Clearance Timothy Sykes | View source ↗ | Timothy Sykes | May 7, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits | ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results Stocktwits | View source ↗ | Stocktwits | May 6, 2026 | neutral | 0 | 0.6 |
| Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data - Benzinga | Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data Benzinga | View source ↗ | Benzinga | May 6, 2026 | neutral | 0 | 0.6 |
| ERNA Stock Explodes Higher As Tiny Biotech Draws Trader Focus - StocksToTrade | ERNA Stock Explodes Higher As Tiny Biotech Draws Trader Focus StocksToTrade | View source ↗ | StocksToTrade | May 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.